ST Renfu announced on September 3 that the RFUS-949 tablets developed by its holding subsidiary Yichang Renfu have recently entered phase II clinical trial research. The drug is intended to be used to treat acute and chronic pain.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.